Michael T. Heffernan's Insider Trades & SAST Disclosures
Michael T. Heffernan's most recent trade in Biohaven Ltd was a trade of 31,716 Stock Options (Right to buy) done . Disclosure was reported to the exchange on May 5, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael T. Heffernan.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biohaven Ltd | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2025 | 31,716 | 31,716 | - | - | Stock Options (Right to buy) | |
| Avalo Therapeutics Inc | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2025 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 4,820 | 50,328 (0%) | 0% | 0 | Common Stock | |
| Trevi Therapeutics Inc | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 7,693 | 45,508 (0%) | 0% | 0 | Common Stock | |
| Biohaven Ltd | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 16,592 | 16,592 | - | - | Stock Option (Right to Buy) | |
| Trevi Therapeutics Inc | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 30,000 | 30,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Synlogic Inc | Michael T. Heffernan | Director | 22 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | ||
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 9,792 | 37,815 (0%) | 0% | 0 | Common Stock | |
| Biohaven Ltd | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 52,906 | 52,906 | - | - | Stock Option (Right to Buy) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2022 | 15,995 | 3,820 | - | - | Stock Option (Right to Purchase) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Sale of securities on an exchange or to another person at price $ 23.63 per share. | 22 Dec 2022 | 15,995 | 28,023 (0%) | 0% | 23.6 | 377,962 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.15 per share. | 22 Dec 2022 | 15,995 | 44,018 (0%) | 0% | 16.1 | 258,319 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2022 | 4,989 | 19,815 | - | - | Stock Option (Right to Purchase) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 22 Dec 2022 | 4,989 | 28,023 (0%) | 0% | 23 | 114,747 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.15 per share. | 22 Dec 2022 | 4,989 | 33,012 (0%) | 0% | 16.1 | 80,572 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2022 | 3,820 | 0 | - | - | Stock Option (Right to Purchase) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Sale of securities on an exchange or to another person at price $ 24.16 per share. | 22 Dec 2022 | 3,820 | 28,023 (0%) | 0% | 24.2 | 92,291 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.15 per share. | 22 Dec 2022 | 3,820 | 31,843 (0%) | 0% | 16.2 | 61,693 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2022 | 237 | 24,804 | - | - | Stock Option (Right to Purchase) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 22 Dec 2022 | 237 | 28,023 (0%) | 0% | 23 | 5,451 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.15 per share. | 22 Dec 2022 | 237 | 28,260 (0%) | 0% | 16.2 | 3,828 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2022 | 46,600 | 25,041 | - | - | Stock Option (Right to Purchase) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Sale of securities on an exchange or to another person at price $ 23.11 per share. | 19 Dec 2022 | 46,600 | 28,023 (0%) | 0% | 23.1 | 1,076,926 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.15 per share. | 19 Dec 2022 | 46,600 | 74,623 (0%) | 0% | 16.2 | 752,590 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.15 per share. | 19 Dec 2022 | 33,758 | 61,781 (0%) | 0% | 16.2 | 545,192 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2022 | 33,758 | 71,641 | - | - | Stock Option (Right to Purchase) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Sale of securities on an exchange or to another person at price $ 23.08 per share. | 19 Dec 2022 | 33,758 | 28,023 (0%) | 0% | 23.1 | 779,135 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2022 | 3,606 | 105,399 | - | - | Stock Option (Right to Purchase) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Sale of securities on an exchange or to another person at price $ 23.04 per share. | 19 Dec 2022 | 3,606 | 28,023 (0%) | 0% | 23.0 | 83,082 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.15 per share. | 19 Dec 2022 | 3,606 | 31,629 (0%) | 0% | 16.2 | 58,237 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Sale of securities on an exchange or to another person at price $ 22.16 per share. | 12 Dec 2022 | 161,687 | 28,023 (0%) | 0% | 22.2 | 3,582,984 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2022 | 94,259 | 0 | - | - | Stock Option (Right to Purchase) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.27 per share. | 12 Dec 2022 | 94,259 | 181,806 (0%) | 0% | 15.3 | 1,439,335 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2022 | 59,524 | 0 | - | - | Stock Option (Right to Purchase) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.90 per share. | 12 Dec 2022 | 59,524 | 87,547 (0%) | 0% | 14.9 | 886,908 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Sale of securities on an exchange or to another person at price $ 22.01 per share. | 12 Dec 2022 | 27,920 | 28,023 (0%) | 0% | 22.0 | 614,519 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2022 | 15,741 | 0 | - | - | Stock Option (Right to Purchase)t to | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.27 per share. | 12 Dec 2022 | 15,741 | 54,433 (0%) | 0% | 15.3 | 240,365 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.90 per share. | 12 Dec 2022 | 10,669 | 38,692 (0%) | 0% | 14.9 | 158,968 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2022 | 10,669 | 0 | - | - | Stock Option (Right to Purchase) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2022 | 7,904 | 0 | - | - | Stock Option (Right to Purchase) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.57 per share. | 12 Dec 2022 | 7,904 | 189,710 (0%) | 0% | 14.6 | 115,161 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2022 | 1,510 | 0 | - | - | Stock Option (Right to Purchase) | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.57 per share. | 12 Dec 2022 | 1,510 | 55,943 (0%) | 0% | 14.6 | 22,001 | Common Stock |
| Biohaven Ltd | Michael T. Heffernan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.50 per share. | 03 Oct 2022 | 9,699 | 15,178 | - | 7.5 | 72,743 | Common Shares |
| Trevi Therapeutics Inc | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Synlogic Inc | Michael T. Heffernan | Director | 09 Jun 2022 | 27,000 | 27,000 | - | - | Stock Option (right to buy) | ||
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 14,035 | 28,023 (0%) | 0% | 0 | Common Stock | |
| Trevi Therapeutics Inc | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,000 | 20,000 | - | - | Nonstatutory Stock Option (right to buy) | |
| Akebia Therapeutics Inc. | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 20,100 | 20,100 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 13,700 | 48,586 (0%) | 0% | 0 | Common Stock | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 9,941 | 13,988 (0%) | 0% | 0 | Common Stock | |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Sale of securities on an exchange or to another person at price $ 25.26 per share. | 15 Mar 2021 | 47,044 | 7,078 (0%) | 0% | 25.3 | 1,188,331 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Sale of securities on an exchange or to another person at price $ 25.88 per share. | 15 Mar 2021 | 3,031 | 4,047 (0%) | 0% | 25.9 | 78,442 | Common Stock |
| Collegium Pharmaceutical Inc | Michael T. Heffernan | Director | Sale of securities on an exchange or to another person at price $ 19.13 per share. | 11 Aug 2020 | 13,071 | 54,122 (0%) | 0% | 19.1 | 250,048 | Common Stock |
| Trevi Therapeutics Inc | Michael T. Heffernan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 14,210 | 14,210 | - | - | Nonstatutory Stock Option (right to buy) | |
| Akebia Therapeutics Inc. | Michael T. Heffernan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 20,100 | 20,100 | - | - | Stock Option (Right to buy) | |
| Akebia Therapeutics Inc. | Michael T. Heffernan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 13,700 | 34,886 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges